Rebuilding the Commercial Playbook

Getting an approved drug to patients has never demanded more coordination. Across nearly every function in bio/pharma commercialization, the playbooks that carried the industry for decades are being rewritten at once, driven by a fragmenting pricing environment, next-generation therapies that strain existing infrastructure, the rapid spread of AI into daily operations, and patients who need more support than ever to get on and stay on therapy. Pharmaceutical Commerce's August 2026 issue arrives in the middle of that reinvention, and the perspectives gathered here capture both its urgency and its promise.

Nowhere is the rethinking more consequential than in pricing and access. The US market has fragmented into three distinct payer economies—commercial, government, and cash—each with its own rules and incentives, pushing manufacturers to manage enterprise value across a product's entire lifecycle rather than optimize a single channel. Direct-to-patient models are reworking the economics of the prescription itself, while real-world evidence is becoming the currency of formulary access, valuable when communicated in a way payers can act on and wasted when it is not. As AI moves deeper into access decisions, it is raising the bar for how manufacturers demonstrate value.

The infrastructure that moves therapies from manufacturer to patient is under equal pressure. Distribution networks built for predictable, bulk volume are being reengineered to carry personalized cell and gene therapies and mass-market GLP-1s, demanding precision and scale at the same time, and the cold chain has become a strategic frontline where packaging alone is no longer enough. Behind the scenes, pharmacovigilance is being transformed by automation, and lifecycle change management, long treated as back-office friction, is now recognized as one of the most addressable operational risks in the enterprise. In each case, AI is proving essential, provided it is governed with discipline rather than adopted on faith.

Closer to the patient, the support ecosystem is being redesigned around continuity and speed. Hub services are being reassessed as operating-model corrections rather than vendor swaps, with patient experience and uninterrupted care as the tests that matter. Launch strategy is being rebuilt around a simple discipline: protect the first hours of the patient journey, prove what works, and expand from there.

Taken together, the articles in this issue present a picture of an industry in active reinvention, confronting the limits of models built for an earlier market while investing in the tools, partnerships, and organizational design required to compete in the next one. The work is far from finished, but the direction is unmistakable, and the professionals leading it are the reason this coverage matters.